Summary of CareDx Conference Call Company Overview - **Company**: CareDx - **Industry**: Life Sciences Tools and Diagnostics Key Highlights 1. **Q1 Performance**: CareDx reported its seventh consecutive quarter of testing services volume growth, with strong performance across heart, kidney, and lung transplantation sectors [2][3] 2. **ISHLT Conference**: Over 60 abstracts from more than 90 transplant centers presented data on CareDx products, indicating broad acceptance and utilization in the transplant community [3] 3. **Surveillance Protocols**: Reactivation of surveillance protocols in transplant centers is expected to contribute to growth, particularly in kidney and heart transplantation [5][6] 4. **Epic Integration**: The integration with Epic is anticipated to drive a volume boost of 10% or greater, with material impacts expected post-2026 [7][8] 5. **AlloSure Launch**: Initial uptake of AlloSure in specialized populations (pediatrics and simultaneous pancreas-kidney transplant patients) has been strong, indicating market validation [9] 6. **Cell Therapy Market**: CareDx is focusing on the cell therapy market, with plans to develop products for allogeneic stem cell transplants, which occur in the same centers as solid organ transplants [10][11] 7. **IOTA Program**: The IOTA program, starting in July, aims to increase kidney transplant volumes by incentivizing centers to utilize more available kidneys [14][16] 8. **Portfolio Approach**: CareDx emphasizes its end-to-end solutions for transplant centers, integrating diagnostics, software, and pharmacy services to enhance patient management [17][18] Financial Insights 1. **Revenue Growth**: The company is targeting a 15% compound annual growth rate (CAGR) through its long-range plan (LRP) [8] 2. **ASP Guidance**: CareDx has guided a blended average selling price (ASP) of $1,360 for the year, with expectations for gradual improvement as contracts are secured [27] 3. **Gross Margins**: Current gross margins for testing services are in the high 70s, with potential for further expansion as ASPs improve [29][30] 4. **Operating Expenses**: The company aims to leverage operating expenses, particularly in R&D and G&A, to achieve a 20% adjusted EBITDA margin target [39][40] Strategic Initiatives 1. **Sales and Marketing Expansion**: CareDx has increased its field force by 50% to enhance customer engagement and protocol adherence [22][23] 2. **CPT Code Impact**: The introduction of a new CPT code for AlloSure is expected to facilitate contracting with payers and improve market access [25][26] 3. **International Expansion**: CareDx is committed to the European market, focusing on evidence generation for AlloSeq cell-free DNA and leveraging distributors for sales [49][50] 4. **Pipeline Development**: The company is actively evaluating opportunities in pre- and post-transplant spaces, with a focus on organic growth and potential inorganic investments [53][55] Competitive Landscape 1. **Brand Value**: CareDx aims to strengthen its brand in the transplant diagnostics market by investing in evidence generation and enhancing customer relationships [62][63] 2. **Unique Value Proposition**: The company differentiates itself by offering a comprehensive solution set that includes software, IVD kits, and pharmacy services, which is not commonly found in the industry [65][66] Underappreciated Aspects - CareDx's comprehensive approach to the transplant market, integrating various services beyond testing, is seen as a significant growth driver that may not be fully recognized by investors [64][66]

CareDx (CDNA) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Good morning. I'm John Hanna, the president and CEO at CareDx. Thank you all for joining us today. This is our safe harbor statement. We may make forward looking statements during the presentation. Please refer to the safe harbor on our website. At CareDx we've built an experienced leadership team in the molecular diagnostics market to drive profitable growth. We have six fifty employees globally, 180 driving our commercial growth in the marke ...

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into CareDx, Inc. for potential breaches of fiduciary duties and violations of federal securities laws [1][2]. Investigation Details - The investigation focuses on actions taken by CareDx insiders between April 30, 2020, and February 24, 2022, which involved issuing false and misleading statements about the company's compliance with healthcare laws and revenue growth [2]. - CareDx began disclosing issues on October 28, 2021, revealing that the company was under multiple government investigations and that its financial results were significantly lower than previously reported [2]. - By November 3, 2022, CareDx's share price had decreased by over 77.22% from its previous levels [2]. Shareholder Information - Current stockholders who have held CareDx stock since at least January 2021 are encouraged to contact Johnson Fistel to discuss their legal rights regarding the investigation [3].

CareDx (CDNA) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this molecular diagnostics company would post earnings of $0.07 per share when it actually produced earnings of $0.18, delivering a surprise of 157.14%.Over the last four quarters, the c ...

CareDx (CDNA) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Caroline Corner - Investor RelationsJohn Hanna - President and CEORobert Woodward - Chief Scientific OfficerAbhishek Jain - CFOKeith Kennedy - Chief Operating OfficerVidyun Bais - Equity Research - Vice PresidentBrandon Couillard - Managing DirectorThomas DeBourcy - PrincipalEduardo Martinez-Montes - Biotechnology Equity Research Associate Conference Call Participants None - AnalystMason Carrico - Research AnalystMatt Stanto ...

The Transplant Solutions Company A P R I L 3 0 , 2 0 2 5 Click to edit Master text styles Click to edit Master title style Patrick G, Kidney Transplant Recipient Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, includin ...

CareDx (CDNA) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to today's CareDx First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star one on your telephone keypad. Please note this call may be recorded, and I will be standing by if you should need a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36536 _ ...

Exhibit 99.1 CareDx Reports First Quarter 2025 Results First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth BRISBANE, Calif., April 30, 2025, CareDx, Inc. (Nasdaq: CDNA) — today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights First Quarter Business Highlights "We had another strong quarter marked by gr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ Form 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH ...